Wistar Institute enters agreement with Christiana Care Graham Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE WISTAR INSTITUTE has entered into an agreement with the Gene Editing Institute at Christiana Care’s Helen F. Graham Cancer Center & Research Institute, expanding their previous partnership established in 2011.

The Gene Editing Institute will be integrated into Wistar’s Molecular Screening Facility. The Gene Editing Institute will retain its management structure and will remain located at the Graham Cancer Center on the Christiana Hospital Campus in Newark, Del. The Molecular Screening Facility will remain housed at Wistar in Philadelphia. According to the two organizations, they have already begun scientific collaborations involving research on melanoma and lung cancer. The previous partnership was the first inter-institutional affiliation between an NCI-designated basic research institution and a community cancer center.

YOU MAY BE INTERESTED IN

By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it.  To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login